Our Science
Our Science
Cutting-edge research and technology
Our initiatives
Our initiatives
Campaigning for a smoke-free future
Smoke-Free Life
Smoke-Free Life
Go beyond your past, make a positive change
pmi-emblem

Why Invest in PMI?

We've built the worlds most succesful cigarette company. Now we're building our future on smoke-free products that are much better choices.

$ 8887

0.00 (0%)

Investor Relations

Latest Press Releases

Media Center
  • Press Release 21 Jan, 2020

    Majority of People Want Governments to Do More to Reduce Smoking Rates, According to a New Global Survey From PMI

  • News 21 Jan, 2020

    Big and small businesses can solve big challenges together

  • News 21 Jan, 2020

    PMI releases “Unsmoke Your Mind: Pragmatic Answers to Tough Questions for a Smoke-Free Future”

  • Press Release 20 Jan, 2020

    PMI Recognized for Its Climate Leadership with Six Consecutive Years on CDP’s ‘A List’ for Climate Change

This site is operated for the purpose of providing general information about us. The site is not operated for advertising or marketing purposes. The material on this site should not be regarded as an offer to sell, or a solicitation of an offer to buy, any product of PMI. Such products are sold only in compliance with the laws of the particular jurisdictions in which they are sold. PMI has now been granted authorization to market IQOS 2.4 in the U.S. from the Food and Drug Administration (FDA), which Altria will bring to the U.S. market under the terms of a license from PMI. The FDA has not yet determined whether IQOS 2.4 meets the standard to be marketed in the U.S. as a modified risk tobacco product. PMI’s applications to the FDA seeking authorization to market IQOSin the U.S. as a modified risk product are currently under review.